Repeated administration of phencyclidine (PCP), an N-methyl-d-aspartate (NMDA) receptor antagonist, during development, may result in neuronal damage that leads to behavioral deficits in adulthood. The present study examined the potential neurotoxic effects of PCP exposure (10 mg/kg) in rats on postnatal days (PNDs) 7, 9 and 11 and the possible underlying mechanism(s) for neurotoxicity. Brain tissue was harvested for RNA extraction and morphological assessments. RNA was collected from the frontal cortex for DNA microarray analysis and quantitative RT-PCR. Gene expression profiling was determined using Illumina Rat Ref-12 Expression BeadChips containing 22,226 probes. Based on criteria of a foldchange greater than 1.4 and a P-value less than 0.05, 19 genes including NMDAR1 (N-methyl-d-aspartate receptor) and four pro-apoptotic genes were up-regulated, and 25 genes including four anti-apoptotic genes were down-regulated, in the PCP-treated group. In addition, the schizophrenia-relevant genes, Bdnf (Brain-derived neurotrophic factor) and Bhlhb2 (basic helix-loop-helix domain containing, class B, 2), were significantly different between the PCP and the control groups. Quantitative RT-PCR confirmed the microarray results. Elevated neuronal cell death was further confirmed using Fluoro-Jade C staining. These findings support the hypothesis that neurodegeneration caused by PCP occurs, at least in part, through the up-regulation of NMDA receptors, which makes neurons possessing these receptors more vulnerable to endogenous glutamate. The changes in schizophrenia-relevant genes after repeated PCP exposure during development may provide important information concerning the validation of an animal model for this disorder.
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Introduction
Schizophrenia is a chronic, severe, and disabling brain disorder that affects about 1% of the world's population (Bromet and Fennig, 1999) . It is characterized by abnormalities in the perception or expression of reality. Schizophrenia affects multiple cognitivebehavioral domains, comprising positive symptoms (e.g., delusion, hallucination, and paranoia), negative symptoms (e.g., loss of motivation, affective blunting and social withdrawal), and cognitive symptoms. Despite intensive studies, its molecular etiology remains enigmatic. Because many drugs that ameliorate psychotic symptoms in patients with schizophrenia are dopamine receptor blockers, much attention has been devoted to the dopamine hyperactivity hypothesis. However, it is difficult to explain the disease solely in terms of an abnormally overactive dopaminergic transmitter system (Olney and Farber, 1995) . Several studies on families, twins, and adoptions suggest the importance of genetic factors in etiology; while clinical studies, advanced imaging techniques such as magnetic resonance imaging (MRI), and novel neuroanatomical markers have provided evidence that schizophrenia is a neurodevelopmental disorder (Sawa and Snyder, 2002) . Some investigators have suggested that NMDA receptor hypofunction may underlie certain features of schizophrenia (Olney and Farber, 1995) . In fact, early in 1980, Kim et al. (1980) first proposed that decreased glutamatergic activity may be involved in the etiology of schizophrenia. The accretion of evidence in support of the hypothesis that hypofunction of NMDA receptors contributes to the 0736-5748/$36.00 Published by Elsevier Ltd on behalf of ISDN doi:10.1016/j.ijdevneu.2010.07.234
